OCEAN

Description

A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared
With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple
Myeloma Who Are Refractory to Lenalidomide